Grail initiated with a Neutral at Mizuho

Mizuho analyst Bradley Bowers initiated coverage of Grail (GRAL) with a Neutral rating and $58 price target Grail is a leader in multicancer early detection testing with its Galleri test as the main product, the analyst tells investors in a research note. The firm says its early physician feedback questions Galleri’s competitive advantage and the most recent data release missed its primary endpoint. It believes a volume inflection is more likely in 2027, after FDA approval.